NASDAQ : EXEL

Exelixis, Inc.

$55.94 USD

-$0.57 (-1.01%)

Volume
725.31K
Average Volume
2.67M
Market Capitalization
$14.06B
P/E Ratio
17.93
Dividend Yield
0.00%
Price Target
$50.50
Year High
$57.57
Year Low
$33.76
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$3.26
Company Overview

NASDAQ

Michael Morrissey

Biotechnology

Healthcare

EXEL

1077

US

USD

https://www.exelixis.com

650 837 7000

30161Q104

0000939767

Liquidity Metrics

0.09

3.26

3.19

0.61

0.00

Sales & Valuation

$2.32B

5.92

7.47

15.34

3.55

Profitability

$2.78

$782.57M

35.08%

42.23%

40.21%

32.13%

P/E Metrics

17.93

0.46

0.46

Analyst Price Target & Rating

$50.50

$56.00

$44.00

Buy

4/5

33 Analysts

10.77%

Financial Health Scores

15.14

7/9

$837.66M

$2.59B

$657.84M

$986.42M

Key Metrics (TTM)

$14.15B

5.96

13.94

3.26

40.21%

35.01%

5.71%

6.45%

$23.32

61 days

Company Executives
Name Title
Christopher J. Senner Executive Vice President & Chief Financial Officer
Michael Morrissey Chief Executive Officer, President & Director
Stefan Krauss Vice President & Head of Business Development
Stelios Papadopoulos Co-Founder & Independent Chair of the Board
William Berg Senior Vice President of Medical Affairs
Deborah Burke Senior Vice President of Finance & Controller
Andrew Ross Peters Senior Vice President of Strategy
Dana T. Aftab Executive Vice President of Research & Development
Brenda Hefti Senior VP & General Counsel
Patrick J. Haley Executive Vice President of Commercial
Poll Results

No votes yet today — be the first to share your view!

About Exelixis, Inc. (NASDAQ:EXEL) Stock

Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several tyrosine kinases such as MET, AXL, RET, and VEGF receptors. Additionally, Exelixis offers COTELLIC, an MEK inhibitor employed in combination therapies for advanced melanoma, and MINNEBRO, an orally administ ... ered, non-steroidal selective mineralocorticoid receptor blocker, approved for hypertension treatment in Japan. The company's developmental pipeline features several promising candidates, such as XL092, an oral tyrosine kinase inhibitor designed to target VEGF receptors, MET, AXL, MER, and other kinases crucial for cancer proliferation; XB002, an antibody-drug conjugate containing a human monoclonal antibody against tissue factor (TF), intended for advanced solid tumors and non-Hodgkin's lymphoma; and XL102, an orally available cyclin-dependent kinase 7 (CDK7) inhibitor being developed for advanced or metastatic solid tumors. Exelixis, Inc. maintains extensive research partnerships and licensing arrangements with numerous pharmaceutical and biotechnology entities, including Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche Ltd., Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solutions, Inc., NBE Therapeutics AG, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., Bristol-Myers Squibb Company, and Daiichi Sankyo Company, Limited. Established in 1994, the company originally operated as Exelixis Pharmaceuticals, Inc. before rebranding to Exelixis, Inc. in February 2000. Its corporate headquarters are located in Alameda, California.

These 3 Healthcare Stocks Have Crushed the Market This Year. Here's Why There's More Upside Ahead

2026-07-24 17:00:00

Krystal Biotech is posting strong sales thanks to a breakthrough in an underserved therapeutic area. Exelixis has carved out a niche in the cancer-drug market, which much larger companies typically dominate.

EXEL vs. ILMN: Which Stock Is the Better Value Option?

2026-07-24 12:41:18

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and Illumina (ILMN). But which of these two stocks is more attractive to value investors?

Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026

2026-07-22 16:30:00

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2026 financial results will be released on Wednesday, August 5, 2026 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event will be available via the Internet from the company's website. To access the conference call, please dial (800) 715-9871 (domes.

Bank of New York Mellon Corp Sells 57,995 Shares of Exelixis, Inc. $EXEL

2026-07-22 03:47:40

Bank of New York Mellon Corp lowered its holdings in shares of Exelixis, Inc. (NASDAQ: EXEL) by 2.8% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,986,035 shares of the biotechnology company's stock after selling 57,995 shares during the

Exelixis (EXEL) Earnings Expected to Grow: Should You Buy?

2026-07-20 11:01:22

Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Allspring Global Investments Holdings LLC Acquires 323,895 Shares of Exelixis, Inc. $EXEL

2026-07-18 03:09:51

Allspring Global Investments Holdings LLC grew its holdings in Exelixis, Inc. (NASDAQ: EXEL) by 23.4% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,707,715 shares of the biotechnology company's stock after acquiring an additional 323,895 shares during the period. Allspring Global

Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?

2026-07-16 13:11:03

Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

3 Under-the-Radar Stocks to Buy and Hold

2026-07-10 14:30:00

These three biotechs are posting strong revenue growth. Brand-new launches and label expansions should help them improve their lineups.

Frequently Asked Questions

What is the current Exelixis, Inc. (EXEL) stock price?

Exelixis, Inc.(NASDAQ:EXEL) stock price is $55.94 in the last trading session. During the trading session, EXEL stock reached the peak price of $57.57 while $33.76 was the lowest point it dropped to. The percentage change in EXEL stock occurred in the recent session was --1.01% while the dollar amount for the price change in EXEL stock was -$0.57.

EXEL's industry and sector of operation?

The NASDAQ listed EXEL is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of EXEL?

Christopher J. Senner | Executive Vice President & Chief Financial Officer
Michael Morrissey | Chief Executive Officer, President & Director
Stefan Krauss | Vice President & Head of Business Development
Stelios Papadopoulos | Co-Founder & Independent Chair of the Board
William Berg | Senior Vice President of Medical Affairs

How many employees does EXEL have?

Number of EXEL employees currently stands at 1077. EXEL operates from 1851 Harbor Bay Parkway, Alameda, CA 94502, US.

Link for EXEL official website?

Official Website of EXEL is: https://www.exelixis.com

How do I contact EXEL?

EXEL could be contacted at phone #650 837 7000 and can also be accessed through its website. EXEL operates from 1851 Harbor Bay Parkway, Alameda, CA 94502, US.

How many shares of EXEL are traded daily?

The average number of EXEL shares traded daily for last 3 months was 2.67M.

What is the market cap of EXEL currently?

The market value of EXEL currently stands at $14.06B with its latest stock price at $55.94